IL202563A - Anti-amyloid antibody in a monoclonal cell - Google Patents

Anti-amyloid antibody in a monoclonal cell

Info

Publication number
IL202563A
IL202563A IL202563A IL20256309A IL202563A IL 202563 A IL202563 A IL 202563A IL 202563 A IL202563 A IL 202563A IL 20256309 A IL20256309 A IL 20256309A IL 202563 A IL202563 A IL 202563A
Authority
IL
Israel
Prior art keywords
monoclonal anti
beta amyloid
amyloid antibody
anti beta
antibody
Prior art date
Application number
IL202563A
Other languages
English (en)
Hebrew (he)
Other versions
IL202563A0 (en
Original Assignee
Genentech Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39790376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL202563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Ac Immune Sa filed Critical Genentech Inc
Publication of IL202563A0 publication Critical patent/IL202563A0/en
Publication of IL202563A publication Critical patent/IL202563A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
IL202563A 2007-06-12 2009-12-07 Anti-amyloid antibody in a monoclonal cell IL202563A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94354307P 2007-06-12 2007-06-12
US94354107P 2007-06-12 2007-06-12
US94379007P 2007-06-13 2007-06-13
PCT/US2008/007317 WO2008156621A1 (en) 2007-06-12 2008-06-12 Monoclonal anti beta amyloid antibody

Publications (2)

Publication Number Publication Date
IL202563A0 IL202563A0 (en) 2011-08-01
IL202563A true IL202563A (en) 2016-05-31

Family

ID=39790376

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202563A IL202563A (en) 2007-06-12 2009-12-07 Anti-amyloid antibody in a monoclonal cell

Country Status (18)

Country Link
EP (2) EP2527366B1 (enExample)
JP (2) JP5436414B2 (enExample)
KR (2) KR20160017126A (enExample)
CN (1) CN101802007B (enExample)
AR (1) AR066987A1 (enExample)
AU (1) AU2008267037B2 (enExample)
BR (1) BRPI0812484A2 (enExample)
CA (1) CA2690434C (enExample)
CL (3) CL2008001742A1 (enExample)
ES (1) ES2548102T3 (enExample)
IL (1) IL202563A (enExample)
MX (1) MX2009013503A (enExample)
NZ (2) NZ601843A (enExample)
PE (2) PE20090831A1 (enExample)
RU (1) RU2571856C2 (enExample)
TW (2) TWI453217B (enExample)
WO (1) WO2008156621A1 (enExample)
ZA (1) ZA201000049B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
AR066987A1 (es) * 2007-06-12 2009-09-23 Ac Immune Sa Anticuerpo monoclonal contra proteina beta-amiloide
CA2701793C (en) * 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
WO2011107507A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EA034333B1 (ru) 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
EP2677032B1 (en) 2011-02-18 2017-11-15 National University Corporation Tokyo University Of Agriculture and Technology Amyloid protein oligomer binding aptamer
CN102921007B (zh) * 2011-08-09 2014-12-10 中国科学院上海生命科学研究院 防治胰岛素抵抗和糖尿病的方法和试剂
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
EA201491920A1 (ru) 2012-05-21 2016-03-31 Дженентек, Инк. Способы повышения безопасности транспорта через гематоэнцефалический барьер
EP4324480A3 (en) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
CN105722532A (zh) 2013-09-13 2016-06-29 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
CA3004498A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3445782A4 (en) * 2016-04-20 2020-01-15 Aelan Cell Technologies, Inc. H1.0 DIMETHYLATED K180 PROTEIN COMPOSITIONS AND METHODS
EP3484919A4 (en) 2016-07-18 2020-03-04 The University of British Columbia ANTI-BETA-AMYLOID ANTIBODIES
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US20210165001A1 (en) * 2018-08-03 2021-06-03 The University Of Hong Kong Compositions and methods for detection and imaging of amyloid fibrils, amyloid plaques, rna, and nucleoli
KR101977410B1 (ko) * 2018-08-22 2019-05-10 주식회사 피플바이오 당뇨병에 대한 신규 바이오마커 및 그의 용도
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN111518206B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
CN111518205B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP3757125A1 (en) * 2019-06-28 2020-12-30 BioArctic AB Antibody directed against the apoe amino-terminal fragment of 12 kda
CN110317814A (zh) * 2019-07-19 2019-10-11 莫丁丁 β-淀粉样蛋白环状核糖核酸、多肽及其应用
WO2021048324A1 (en) * 2019-09-10 2021-03-18 Ac Immune Sa Novel molecules for diagnosis
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN110687035A (zh) * 2019-10-10 2020-01-14 沈阳万类生物科技有限公司 Annexin V-Light 650凋亡检测试剂盒
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
CN113308439B (zh) * 2020-11-06 2023-05-05 华中科技大学 分泌人淀粉样蛋白-β单克隆抗体的杂交瘤细胞株及其应用
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
CN113057963B (zh) * 2021-03-31 2022-05-20 华中科技大学 一种用于清除β-淀粉样蛋白的特异性捕获载体及其应用
CN113311153B (zh) * 2021-05-12 2023-05-26 华中科技大学 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
KR102565471B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 cbrv1-04369 및 이를 포함하는 알츠하이머병 치료용 조성물
KR102565470B1 (ko) * 2022-08-04 2023-08-10 가천대학교 산학협력단 아밀로이드 베타 특이적 펩타이드 sma_04088-2 및 이를 포함하는 알츠하이머병 치료용 조성물
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
CN119390832A (zh) * 2024-10-12 2025-02-07 中国科学技术大学 一种兔源Aβ 1-40单克隆抗体、制备方法及应用
CN120098147B (zh) * 2025-05-07 2025-07-15 中山大学 一种纳米自组装抗Aβ抗体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
ZA938243B (en) * 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
CA2127476C (en) 1994-07-06 1999-12-07 Daniel G. Pomerleau Logging or measurement while tripping
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
DE852011T1 (de) * 1995-09-14 2001-10-11 Scripps Res Inst La Jolla Für natives prp-sc spezifische antikörper
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
CA2634294A1 (en) 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
DE60226036T9 (de) * 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
US7060270B2 (en) * 2001-11-02 2006-06-13 Diagenics International Corporation Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
JP2006512417A (ja) 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
WO2004065569A2 (en) * 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
BRPI0610093A2 (pt) * 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
ES2856451T3 (es) * 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
SG10201706600VA (en) * 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR066987A1 (es) * 2007-06-12 2009-09-23 Ac Immune Sa Anticuerpo monoclonal contra proteina beta-amiloide

Also Published As

Publication number Publication date
TWI516500B (zh) 2016-01-11
AR066987A1 (es) 2009-09-23
AU2008267037A1 (en) 2008-12-24
JP2010530227A (ja) 2010-09-09
ES2548102T3 (es) 2015-10-13
CA2690434A1 (en) 2008-12-24
RU2571856C2 (ru) 2015-12-20
EP2527366B1 (en) 2017-08-16
JP2014087353A (ja) 2014-05-15
KR20100027216A (ko) 2010-03-10
CL2012001817A1 (es) 2012-12-14
JP5436414B2 (ja) 2014-03-05
NZ581835A (en) 2012-09-28
CL2008001742A1 (es) 2008-11-21
HK1140500A1 (en) 2010-10-15
EP2170953B1 (en) 2015-07-15
EP2170953A1 (en) 2010-04-07
CN101802007B (zh) 2017-08-25
RU2010100354A (ru) 2011-07-20
IL202563A0 (en) 2011-08-01
CA2690434C (en) 2018-05-22
NZ601843A (en) 2014-01-31
KR101600095B1 (ko) 2016-03-07
TWI453217B (zh) 2014-09-21
PE20090831A1 (es) 2009-07-10
EP2527366A1 (en) 2012-11-28
BRPI0812484A2 (pt) 2018-06-05
KR20160017126A (ko) 2016-02-15
AU2008267037B2 (en) 2014-08-07
CN101802007A (zh) 2010-08-11
PE20131141A1 (es) 2013-10-14
WO2008156621A1 (en) 2008-12-24
ZA201000049B (en) 2018-11-28
TW200906852A (en) 2009-02-16
MX2009013503A (es) 2010-01-27
CL2012000631A1 (es) 2012-10-05
TW201441256A (zh) 2014-11-01

Similar Documents

Publication Publication Date Title
IL202563A0 (en) Monoclonal anti beta amyloid antibody
IL196478A0 (en) Humanized antibody against amyloid beta
PL2074145T3 (pl) Humanizowane przeciwciało przeciw amyloidowi beta
ZA200908870B (en) Humanized antibodies to amyloid beta
SI2178921T1 (sl) Monoklonska protitelesa proti glipikan-3
HRP20181616T1 (hr) Potpuno ljudska anti-vap-1 monoklonska antitijela
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
SG10201601279SA (en) Monoclonal Antibody STRO-4
DE602008004769D1 (en) Hetarylaniline als modulatoren für amyloid beta
IL204835A0 (en) Humanized antibody
EP2331579A4 (en) MONOCLONAL ANTIBODIES
CR20170001A (es) Anticuerpos anti factor d humanizados
IL205502A0 (en) Humanized antibodies against tl1a
PL2121754T3 (pl) Pegylowany FAB amyloidu beta
PT2379601T (pt) Anticorpo anti-idiotípico contra um anticorpo contra o péptido β-amiloide
EP2198055A4 (en) HUMANIZED PAI-1 ANTIBODIES
IL254065B (en) Human antibody against amyloid in the cell
ZA200900313B (en) Humanized antibody against amyloid beta
GB0706963D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
GB0706965D0 (en) Humanized antibody
ECSP088085A (es) Metodos de purificacion anticuerpos anti a beta

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed